Multiple sclerosis risk sharing scheme: a costly failure.
Raftery
James
J
Wessex Institute, School of Medicine, University of Southampton, Southampton SO167NS. raftery@soton.ac.uk
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D000068717:Glatiramer Acetate; D006297:Health Services Accessibility / Q000191:economics / Q000458:organization & administration*; D006801:Humans; D016899:Interferon-beta / Q000191:economics / Q000600:supply & distribution; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000191:economics; D010455:Peptides / Q000191:economics / Q000600:supply & distribution; D020414:Risk Sharing, Financial; D013222:State Medicine / Q000191:economics
D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta